Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Rheumatoid Arthritis Market expected to increase with a decent CAGR of approx. 3% during the study period 2017-30


LAS VEGAS, Oct. 29, 2020 /PRNewswire/ -- The Rheumatoid Arthritis market report delivers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan for the study period of 2017-2030.

DelveInsight_Logo

Few of the key highlights from the report:

To know how the trends will be impacting the market, click on the link to download the sample: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market 

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory autoimmune disease and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Even after years of research, the cause of rheumatoid arthritis is still unknown. Rheumatoid Arthritis symptoms include joint pain, stiffness, swelling, and decreased movement of the joints. Rheumatoid arthritis diagnosis is done by a combination of patient's symptoms, results of doctor's examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of Rheumatoid Arthritis -specific autoantibodies. Rheumatoid Arthritis has a predilection to affect women, that's why the incidence and prevalence rates in women for RA is 2- 3 times more as compared to men. The total prevalent cases of Rheumatoid Arthritis in the 7MM were observed to be 4,356,793 in 2017 which are estimated to rise during the study period (2017?2030). The United States accounted for the highest number of cases in the 7MM.

The report provides an in-depth historical and forecasted analysis of Rheumatoid Arthritis Epidemiology segmented by:

Rheumatoid Arthritis Treatment Market 

The Rheumatoid Arthritis treatment paradigm includes medicine, supportive treatment and surgery. Currently, there are three primary treatment options for severe and advancing Rheumatoid Arthritis which include DMARDs, NSAIDs, and corticosteroids. Rheumatoid market consists of many different drug target agents forming different drug classes. Conventional DMARDs are a group of drugs (i.e. methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that have been shown to affect the underlying cause of RA by damping down over-activity of the immune system, which helps to ease pain, swelling and stiffness, and prevent changes occurring within the joint. Among csDMARDS, methotrexate (MTX) is considered as a part of the first treatment strategy. MTX remains the anchor drug in RA; along with usage as monotherapy, it is also the basis for combination therapies, either with GC or with other csDMARDs, bDMARDs or tsDMARDs.Patients refractory to csDMARDS or with severe symptoms usually treated with a wide variety of biologics DMARDs classes like anti-TNF, T cell inhibitor, B cell Inhibitor, Interleukin Inhibitors and targeted synthetic DMARDs like JAK Inhibitors. The drug classes include blockbusters Anti-TNF (Etanercept, Infliximab, Adalimumab, Certolizumab-pegol) JAK inhibitors (tofa citinib, baricitinib, upadacitinib, Peficitinob) B-cell inhibitors (Rituximab), Interleukin Inhibitors (Tocilizumab, Sarilumab), T-cell inhibitors (Abatacept), DMARDs, other novel inhibitors, etc.

Biological DMARDs showed promising results in treating RA patients and market penetration is expected to be more in the future and this class is expected to drive the growth of the market. Oral classes such as JAKi and upcoming BTKi due to patient convenient RoA are also expected to contribute to the Rheumatoid Arthritis market growth. The market for Rheumatoid Arthritis possesses fierce competition but still, there is a high demand for new therapies having similar or better efficacy, however, improved safety profile as well as patient adherence. Because of high competition, the new entrants are expected to be met with some resistance and will experience slow uptake, as the market is currently dominated by the anti-TNFs and entry of biosimilars will further pose significant challenges to new and upcoming treatment. It goes without saying that the dynamics of the Rheumatoid Arthritis market is expected to change because of the launch of emerging therapies, companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Gilead and Galapagos NV [Filgotinib (GS-6034; Jyseleca)], and R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Merck KGaA (Evobrutinib), Pfizer (PF-06650833, and PF-06651600), Roche (Fenebrutinib), and several others in phase II clinical development stage with their investigational candidates.

As many potential therapies are being investigated for the management of Rheumatoid Arthritis, it is for sure that the treatment space will experience a significant impact during the forecast period of 2020?2030.

As the emerging drugs will be entering the market, to know what will be their impact on the existing market, which drug will be a blockbuster, and for which line of treatment these drugs will be used? Download the RA Report to know more:- https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market 

Scope of the Report

Table of Contents

1.  Key Insights

2.  Executive Summary of Rheumatoid Arthritis

3.  SWOT Analysis of Rheumatoid Arthritis

4.  Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Country

5.  Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Class

6.  Rheumatoid Arthritis Disease Background and Overview

7.  Rheumatoid Arthritis Epidemiology and Patient Population

8.  Rheumatoid Arthritis Epidemiology Scenario: 7MM

9.  The United States Rheumatoid Arthritis Epidemiology

10.  EU-5 Rheumatoid Arthritis Epidemiology

10.1. Germany

10.2. France

10.3. Italy

10.4. Spain

10.5. The United Kingdom

11.  Japan Rheumatoid Arthritis Epidemiology

12.  Current Rheumatoid Arthritis Treatment Practices

12.1. Medications

12.2. Supportive Treatment

12.3. Surgery

12.4. Treatment Algorithm

12.5. Guideline of Rheumatoid Arthritis 

13.  Unmet Needs

14.  Patient Journey of Rheumatoid Arthritis

15.  Key Endpoints in Rheumatoid Arthritis Clinical Trials

16.  Rheumatoid Arthritis Marketed Therapies

16.1. Marketed Therapies Key Cross

16.2. Olumiant (Barticinib): Eli Lilly and Company/Incyte Corporation

16.3. Rinvoq (Upadacitinib): AbbVie

16.4. Xeljanz (Tofacitinib): Pfizer/PV PRISM CV

16.5. Remicade (Infliximab): Janssen Biotech (Centocor)

16.6. Enbrel (Etanercept): Immunex/Amgen

16.7. Rituxan/MabThera (Rituximab): Genentech/Biogen

16.8. Certolizumab-pegol (Cimzia): UCB Inc.

16.9. Golimumab (Simponi): Janssen Biotech

16.10.  Humira (adalimumab): AbbVie

16.11.  Orencia (Abatacept): Bristol Myers Squibb

16.12.  Smyraf (Peficitinib): Astella Pharma

16.13.  Actemra (Tocilizumab): Roche

16.14.  Kineret (Anakinra): Swedish Orphan Biovitrium (SOBI)

16.15.  Kevzara (Sarilumab): Regeneron and Sanofi

17.  Rheumatoid Arthritis Emerging Therapies

17.1. Key Cross

17.2. GSK3196165 (otilimab/MOR103): GlaxoSmithKline

17.3. Filgotinib (GS-6034; GLPG0634; Jyseleca): Gilead and Galapagos NV

17.4. Olokizumab: R-Pharm

17.5. TS-152 (Ozoralizumab): Taisho Pharmaceuticals

17.6. ATI-450 (CDD-450): Aclaris Therapeutics

17.7. VIB4920: Viela Bio

17.8. Branebrutinib: Bristol Myers Squibb

17.9. ABBV-3373 and ABBV-154: AbbVie

17.10.  Dekavil (F8IL10): Pfizer/Philogen

17.11.  PF-06651600 (Ritlecitinib): Pfizer

17.12.  JTE 051: Akros Pharma/Japan Tobacco

17.13.  Evobrutinib (M2951): Merck KGaA

17.14.  PF-06650833: Pfizer

17.15.  Fenebrutinib (GDC-0853, RG7845): Genentech (subsidiary of Roche)

17.16.  MPC-300-IV (Allogeneic Mesenchymal Precursor Cells): Mesoblast

17.17.  Bimekizumab: UCB Pharma/PRA HEALTH SCIENCES

17.18.  Namilumab (IZN-101; AMG203): Izana Bioscience/Takeda

17.19.  ABX464: Abivax S.A.

17.20.  HB-AdMSCs: Hope Biosciences

17.21.  SKI-O-703: Genosco (Oscotec)

18.  Conjoint Analysis of Rheumatoid Arthritis

19.  Rheumatoid Arthritis Seven Major Market Analysis

20.  7MM Rheumatoid Arthritis Market Size

21.  United States Rheumatoid Arthritis Market Size

22.  EU-5 Rheumatoid Arthritis Market Size

22.1. Germany Market Size

22.2. France Market Size

22.3. Italy Market Size

22.4. Spain Market Size

22.5. United Kingdom Market Size

23.  Japan Rheumatoid Arthritis Market Size

24.  Market Access and Reimbursement of Rheumatoid Arthritis Therapies

25.  Rheumatoid Arthritis Market Drivers

26.  Rheumatoid Arthritis Market Barriers

27.  Appendix

28.  DelveInsight Capabilities

29.  Disclaimer

30.  About DelveInsight

Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Related Reports

Rheumatoid Arthritis - Epidemiology Forecast to 2030

DelveInsight's Rheumatoid Arthritis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Rheumatoid Arthritis.

Rheumatoid Arthritis - Pipeline Insights, 2020

Rheumatoid Arthritis (RA) - Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Rheumatoid Arthritis (RA) market.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur
info@delveinsight.com 
+91-9650213330
DelveInsight

 

SOURCE DelveInsight Business Research, LLP


These press releases may also interest you

at 15:45
Students with a love of STEM and an interest in health care can prepare for a career that prioritizes both with Florida Polytechnic University's new Health Systems Engineering (HSE) program, which offers the only undergraduate-level concentration of...

at 15:40
HUMANETICS GROUP, the global safety, sensor and precision engineering business, announced today that Amit Singhi has joined the Humanetics Group as Chief Financial Officer (CFO) reporting to Chris O'Connor, President and CEO. Chris O'Connor,...

at 15:20
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavretotm (pralsetinib) for the treatment of adult and pediatric patients 12 years of age and older...

at 15:15
Blueprint Medicines Corporation , a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETOtm (pralsetinib) for...

at 15:07
Riverain Technologiestm will showcase its artificial intelligence solutions and enhancements at the now-virtual 2020 Radiological Society of North America Annual Meeting (RSNA). Radiologists spend a significant amount of time on mundane reporting and...

at 15:01
Korean start-up Looxid Labs Inc, will unveil 'LUCY' - a cognitive care solution founded in biotechnology, at the forthcoming Facebook Accelerator Seoul Demo Day on Dec. 2, 2020. Developed for an ageing population, LUCY is a powerful virtual-reality...



News published on 29 october 2020 at 09:48 and distributed by: